Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 2,911 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Lithium Carbonate, Riluzole, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 19 more

Conditions: Acute Pain
Interventions: Placebo, LY3023703, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Myasthenia Gravis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Fresno, California • Orange, California • San Francisco, California + 12 more

Conditions: Obstructive Sleep Apnea
Interventions: AD036, Atomoxetine, Placebo; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Little Rock, Arkansas • Santa Ana, California • Chevy Chase, Maryland + 2 more

Conditions: Knee Osteoarthritis
Interventions: Hylan G-F 20, Control; Device · Other
Lead sponsor: OhioHealth; Other
Eligibility: 40 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lactation
Interventions: Similac Prenatal Vitamin soft-gel capsule, Placebo (soybean oil and dl-alpha-tocopheryl acetate); Dietary Supplement
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Dayton, Ohio • Kettering, Ohio + 3 more

Conditions: Partial Epilepsy
Interventions: YKP3089, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 16
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 12 more

Conditions: Healthy
Interventions: Placebo, Dietary Supplement with actives; Dietary Supplement
Lead sponsor: Olly, PBC; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Lisdexamfetamine Dimesylate (Vyvanse), Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 112
States / cities: Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Pridopidine, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Pain
Interventions: Palmitoylethanolamide 600mg twice a day, placebo; Drug · Other
Lead sponsor: Navy Medical Center San Diego; Federal
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stress, Anxiety
Interventions: Proprietary Blend of Ashwagandha, KSM-66 Ashwagandha root extract, Placebo; Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Addiction
Interventions: Risperidone, Ziprasidone, Oxycodone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Placebo, VE303, oral vancomycin; Drug
Lead sponsor: Patricia Bloom; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Fatigue
Interventions: Placebo, Medical Food - Anhydrous Enol-Oxaloacetate; Other
Lead sponsor: Terra Biological LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atrial Fibrillation
Interventions: Milvexian, Apixaban, Placebo, Apixaban Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 216
States / cities: Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more

Conditions: Overactive Bladder
Interventions: Dried Cranberry, Placebo Oral Capsule; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Bipolar Disorder
Interventions: Aripiprazole, fish oil, Placebo; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more

Conditions: Elevated S-adenosylhomocysteine
Interventions: Alpha-GPC, Creatine and Ashwagandha (Sensoril®), Placebo; Dietary Supplement · Other
Lead sponsor: Standard Process Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: South Gate, California

Conditions: Osteopenia, Osteoporosis
Interventions: Micronized Calcium Carbonate, Non-Micronized Calcium Carbonate, Vitamin D3; Dietary Supplement
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Search by objective public record fields.

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Crossover Trial of AD036 in Obstructive Sleep Apnea

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

Lactation Fortification Study

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

HEALEY ALS Platform Trial - Regimen D Pridopidine

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

Reducing the Abuse Liability of Prescription Opioids

VE303 for Treatment of Hepatic Encephalopathy (HE)

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels

A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD